Travoprost (BioDeep_00000027104)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester

化学式: C26H35F3O6 (500.2385606)
中文名称: 曲伏前列腺素
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O
InChI: InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1

描述信息

Travoprost is only found in individuals that have used or taken this drug. Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin F2alpha analogue. [Wikipedia]Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.
S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EE - Prostaglandin analogues
C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
C78568 - Prostaglandin Analogue

同义名列表

15 个代谢物同义名

(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid; propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; 5,6-trans-Travoprost; Travoprostum; Z, Travatan; Travatan Z; Travaprost; Travoprost; Travatan



数据库引用编号

11 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Büşra Çalışkan, Yeliz Demir, Cüneyt Türkeş. Ophthalmic drugs: in vitro paraoxonase 1 inhibition and molecular docking studies. Biotechnology and applied biochemistry. 2022 Dec; 69(6):2273-2283. doi: 10.1002/bab.2284. [PMID: 34786760]
  • Sven Schnichels, José Hurst, Jan Willem de Vries, Sami Ullah, Agnieszka Gruszka, Minseok Kwak, Marina Löscher, Sascha Dammeier, Karl-Ulrich Bartz-Schmidt, Martin S Spitzer, Andreas Herrmann. Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment. Nanomedicine : nanotechnology, biology, and medicine. 2020 10; 29(?):102260. doi: 10.1016/j.nano.2020.102260. [PMID: 32629041]
  • Yukihisa Takada, Osamu Yamanaka, Yuka Okada, Takayoshi Sumioka, Peter S Reinach, Shizuya Saika. Effects of a prostaglandin F2alpha derivative glaucoma drug on EGF expression and E-cadherin expression in a corneal epithelial cell line. Cutaneous and ocular toxicology. 2020 Jun; 39(2):75-82. doi: 10.1080/15569527.2020.1722152. [PMID: 31986917]
  • Erin Stahl, Dominique Bremond-Gignac, Theresa Landry, Mike Curtis, Kinfemichael Gedif, Sami Al Shahwan, El Roy Dixon. Pharmacokinetics and Safety of Travoprost 0.004\% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2017 06; 33(5):361-365. doi: 10.1089/jop.2016.0133. [PMID: 28437175]
  • Iwona Dams, Jaromir Wasyluk, Marek Prost, Andrzej Kutner. Therapeutic uses of prostaglandin F(2α) analogues in ocular disease and novel synthetic strategies. Prostaglandins & other lipid mediators. 2013 Jul; 104-105(?):109-21. doi: 10.1016/j.prostaglandins.2013.01.001. [PMID: 23353557]
  • Georgi A Georgiev, Norihiko Yokoi, Slavyana Ivanova, Rumen Krastev, Zdravko Lalchev. Surface chemistry study of the interactions of pharmaceutical ingredients with human meibum films. Investigative ophthalmology & visual science. 2012 Jul; 53(8):4605-15. doi: 10.1167/iovs.12-9907. [PMID: 22695955]
  • Hee Young Choi, Ji Eun Lee, Ji Woong Lee, Hyun Jun Park, Ji Eun Lee, Jae Ho Jung. In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2012 Apr; 28(2):146-52. doi: 10.1089/jop.2011.0160. [PMID: 22107041]
  • D Călugăru, M Călugăru. [Monotherapy with lipid structural derivatives in glaucoma]. Oftalmologia (Bucharest, Romania : 1990). 2010; 54(2):30-43. doi: ". [PMID: 20827909]
  • Sudharshan Hariharan, Mukul Minocha, Gyan P Mishra, Dhananjay Pal, Rohit Krishna, Ashim K Mitra. Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2009 Dec; 25(6):487-98. doi: 10.1089/jop.2009.0049. [PMID: 20028257]
  • D Călugăru, M Călugăru. [Bimatoprost therapy in glaucoma]. Oftalmologia (Bucharest, Romania : 1990). 2009; 53(3):34-45. doi: ". [PMID: 19899545]
  • John G Walt, Jacob T Wilensky, Richard Fiscella, Tina H Chiang, Angela Guckian. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis. Clinical drug investigation. 2007; 27(12):819-25. doi: 10.2165/00044011-200727120-00003. [PMID: 18020539]
  • Steven Kymes. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. American journal of ophthalmology. 2006 Aug; 142(2):354; author reply 354-5. doi: 10.1016/j.ajo.2006.04.022. [PMID: 16876536]
  • Robert J Noecker, John G Walt. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. American journal of ophthalmology. 2006 Jan; 141(1 Suppl):S15-21. doi: 10.1016/j.ajo.2005.06.030. [PMID: 16389056]
  • Stefan Holmstrom, Patricia Buchholz, John Walt, Jannie Wickstrøm, Mark Aagren. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Current medical research and opinion. 2005 Nov; 21(11):1875-83. doi: 10.1185/030079905x65600. [PMID: 16307709]
  • N A Sharif, C R Kelly, J Y Crider, G W Williams, S X Xu. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2003 Dec; 19(6):501-15. doi: 10.1089/108076803322660422. [PMID: 14733708]
  • Curtis R Kelly, Gary W Williams, Najam A Sharif. Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. The Journal of pharmacology and experimental therapeutics. 2003 Jan; 304(1):238-45. doi: 10.1124/jpet.102.042556. [PMID: 12490597]
  • N A Sharif, C R Kelly, G W Williams. Bimatoprost (Lumigan((R))) is an agonist at the cloned human ocular FP prostaglandin receptor: real-time FLIPR-based intracellular Ca(2+) mobilization studies. Prostaglandins, leukotrienes, and essential fatty acids. 2003 Jan; 68(1):27-33. doi: 10.1016/s0952-3278(02)00232-6. [PMID: 12538087]
  • B A McCue, M M Cason, M A Curtis, R D Faulkner, D C Dahlin. Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS. Journal of pharmaceutical and biomedical analysis. 2002 Apr; 28(2):199-208. doi: 10.1016/s0731-7085(01)00644-6. [PMID: 11929662]
  • G Ferrari, G V Scagliotti. Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. European journal of cancer (Oxford, England : 1990). 1996 Dec; 32A(13):2368-9. doi: 10.1016/s0959-8049(96)00272-9. [PMID: 9038626]